Magnesium Sulfate (Magnesium Sulfate) Patent Expiration, LOE Window & CMS Spending
Magnesium Sulfate (Magnesium Sulfate) by Fresenius Kabi: Off-Patent Genericized (AB Competition), 8 AB generics, $20.5M 2024 CMS Part D & Medicaid spend, and 17 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Fresenius Kabi |
| FDA Application & Pathway | N019316 (NDA) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 8 |
| 2024 CMS Total Public Spend | $20.5M |
| 2024 Medicare Part D Spend | $174K |
| 2024 Medicaid Spend | $20.3M |
| Reported Wholesale Price Change (CA SB 17) | 17 WAC filings (max 173.9% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.